A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol
David Pryor, Mathias Bressel, Nathan Lawrentschuk, Ben Tran, Jennifer Mooi, Jeremy Lewin, Arun Azad, Duncan Colyer, Nitika Neha, Mark Shaw, Sarat Chander, Paul Neeson, Daniel Moon, Katharine Cuff, Simon Wood, Declan G Murphy, Shahneen Sandhu, Sherene Loi, Shankar Siva
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS | ELSEVIER INC | Published : 2021
Background: The management of oligometastatic clear cell renal cell carcinoma (ccRCC) varies widely, ranging from observation to resection or systemic therapies. Prolonged survival has been observed following resection or stereotactic ablative body radiotherapy (SABR). Immunotherapy combinations have shown survival benefits, however, toxicity is higher than that for monotherapy and complete response rates remain less than 10%. The combination of effective local therapies in conjunction with immunotherapy may provide more durable control and pre-clinical models have suggested a synergistic immune-priming effect of SABR. Objectives: and Methods: RAPPORT is a prospective, single arm, phase I/II..View full abstract
Funding support from Peter MacCallum Foundation philanthropic donation, drug supply by Merck Sharpe Dohme (MSD).